TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcome Measures For Physiotherapy Trials of Airway Clearance in Adults With Cystic Fibrosis
Brief Summary: This is a randomised controlled cross-over trial involving adult cystic fibrosis (CF) patients from the Royal Brompton Hospital, London investigating outcome measures used in airway clearance trials.

Each participant will attend the research facility for two visits. Participants will be randomly assigned to the order that they perform the study sessions. Visit A will involve a period of rest for up to 60 minutes in-between assessments; Visit B will involve a session of airway clearance (ACT) utilising ACBT supervised by a specialist physiotherapist in adult CF.

Participants will perform the outcome measure (OM) tests of impulse oscillation system (IOS), lung clearance index (LCI), and spirometry, then either rest (visit A) or perform a supervised ACBT session (visit B) using electronic impedance tomography (EIT) during the session. IOS, LCI and spirometry will be repeated after the session. Sputum will be collected throughout the ACT or rest sessions and for 30 minutes after each of these sessions is completed. Questionnaires asking patient views on the OMs will be completed at the end of each study visit.

Analysis will be based upon differences in outcome measures and in-between study days.


Options:
A: Arm Label: Usual Airway Clearance Technique; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual airway clearance | Arm Label: High Frequency Chest Wall Oscillation (HFCWO); Type: EXPERIMENTAL; Interventions: Device: High Frequency Chest Wall Oscillation (HFCWO) | Intervention Type: DEVICE; Name: High Frequency Chest Wall Oscillation (HFCWO); Assigned to Arm(s): High Frequency Chest Wall Oscillation (HFCWO) | Intervention Type: OTHER; Name: Usual airway clearance; Assigned to Arm(s): Usual Airway Clearance Technique
B: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
C: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
D: Arm Label: Visit A; Type: ACTIVE_COMPARATOR; Interventions: Other: Rest period | Arm Label: Visit B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT) | Intervention Type: PROCEDURE; Name: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT); Assigned to Arm(s): Visit B | Intervention Type: OTHER; Name: Rest period; Assigned to Arm(s): Visit A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Massage Therapy and Hypopressive Abdominal Exercises on Chronic Non-specific Low Back Pain, Joint Mobility, Disability and the Patient's Quality of Life. A Controlled Clinical Trial
Brief Summary: The main goal of this study is to get to know if applying both, massotherapy plus hypopressive abdominal gymnastics (H.A.G) will reduce the pain of chronic non-specific low back pain. It actually reduces the inability produced by the pain and improve the patient's quality of life as well as the join range of the lumbar spine, way more than these two therapies applied separately.


Options:
A: Arm Label: RESTORE Intervention; Type: EXPERIMENTAL; Interventions: Other: RESTORE Intervention | Arm Label: Control Group 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: RESTORE Intervention; Assigned to Arm(s): RESTORE Intervention
B: Arm Label: GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC; Type: EXPERIMENTAL; Interventions: Procedure: GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC | Arm Label: GROUP RECEIVING MASSOTHERAPY; Type: EXPERIMENTAL; Interventions: Procedure: GROUP RECEIVING MASSOTHERAPY | Arm Label: GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC; Type: EXPERIMENTAL; Interventions: Procedure: GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC | Intervention Type: PROCEDURE; Name: GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC; Assigned to Arm(s): GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC | Intervention Type: PROCEDURE; Name: GROUP RECEIVING MASSOTHERAPY; Assigned to Arm(s): GROUP RECEIVING MASSOTHERAPY | Intervention Type: PROCEDURE; Name: GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC; Assigned to Arm(s): GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC
C: Arm Label: Physical Activity Only; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Physical Activity + Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity, Behavioral: Cognitive Behavioral Therapy | Arm Label: Wait List Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity + Cognitive Behavioral Therapy, Physical Activity Only | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Physical Activity + Cognitive Behavioral Therapy
D: Arm Label: Pilates 1; Type: EXPERIMENTAL; Interventions: Device: Pilates 1 | Arm Label: Pilates 2; Type: EXPERIMENTAL; Interventions: Device: Pilates 2 | Arm Label: Pilates 3; Type: EXPERIMENTAL; Interventions: Device: Pilates 3 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Control | Intervention Type: DEVICE; Name: Pilates 1; Assigned to Arm(s): Pilates 1 | Intervention Type: DEVICE; Name: Pilates 2; Assigned to Arm(s): Pilates 2 | Intervention Type: DEVICE; Name: Pilates 3; Assigned to Arm(s): Pilates 3 | Intervention Type: DEVICE; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of An Innovative Smartphone Intervention for Smoking Cessation
Brief Summary: The goal of this study is to determine whether the novel smartphone app (SmartQuit) provides higher quit rates than the current standard smoking cessation app.


Options:
A: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: Acceptance Therapy (ACT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Acceptance Therapy (ACT); Assigned to Arm(s): ACT | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control
C: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
D: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: ACT | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Intervention Type: BEHAVIORAL; Name: ACT; Assigned to Arm(s): ACT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of An Innovative Smartphone Intervention for Smoking Cessation
Brief Summary: The goal of this study is to determine whether the novel smartphone app (SmartQuit) provides higher quit rates than the current standard smoking cessation app.


Options:
A: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
B: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: ACT | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Intervention Type: BEHAVIORAL; Name: ACT; Assigned to Arm(s): ACT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT
C: Arm Label: WebQuit study group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit study group | Arm Label: WebQuit control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit control group | Intervention Type: BEHAVIORAL; Name: WebQuit study group; Assigned to Arm(s): WebQuit study group | Intervention Type: BEHAVIORAL; Name: WebQuit control group; Assigned to Arm(s): WebQuit control group
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised Study
Brief Summary: Objectives: Occlusal surfaces of erupting permanent molars are highly prone to caries. Self-assembling peptide (P11-4) has proven to enhance biomimetic mineralization of early carious lesions. Aim of this study was to evaluate safety, clinical applicability and effect of using P11-4 (Curodont™ Repair) in non-invasive treatment of early occlusal lesions.

Methods: 70 patients with active early occlusal lesions (ICDAS-II:1-3) on first or second permanent molars at eruption will be allocated in this randomized, controlled, single blinded study to test (Curodont™ Repair+Duraphat®) or control (Duraphat®) groups.


Options:
A: Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Arm Label: Non-Restorative Caries Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Non-Restorative Caries Treatment | Arm Label: Conventional Restoration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Restoration | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique | Intervention Type: PROCEDURE; Name: Non-Restorative Caries Treatment; Assigned to Arm(s): Non-Restorative Caries Treatment | Intervention Type: PROCEDURE; Name: Conventional Restoration; Assigned to Arm(s): Conventional Restoration
B: Arm Label: Simple Prevention; Type: EXPERIMENTAL; Interventions: Device: Silver Diamine Fluoride, Device: Fluoride Varnishes | Arm Label: Complex prevention; Type: ACTIVE_COMPARATOR; Interventions: Device: Fluoride Varnishes, Device: Glass Ionomer | Intervention Type: DEVICE; Name: Silver Diamine Fluoride; Assigned to Arm(s): Simple Prevention | Intervention Type: DEVICE; Name: Fluoride Varnishes; Assigned to Arm(s): Complex prevention, Simple Prevention | Intervention Type: DEVICE; Name: Glass Ionomer; Assigned to Arm(s): Complex prevention
C: Arm Label: Selective removal; Type: EXPERIMENTAL; Interventions: Procedure: Selective removal | Arm Label: Stepwise removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stepwise removal | Intervention Type: PROCEDURE; Name: Selective removal; Assigned to Arm(s): Selective removal | Intervention Type: PROCEDURE; Name: Stepwise removal; Assigned to Arm(s): Stepwise removal
D: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Device: self assembling peptide P11-4 (Curodont™ Repair), Device: fluoride varnish (Duraphat®) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: fluoride varnish (Duraphat®) | Intervention Type: DEVICE; Name: self assembling peptide P11-4 (Curodont™ Repair); Assigned to Arm(s): intervention | Intervention Type: DEVICE; Name: fluoride varnish (Duraphat®); Assigned to Arm(s): control, intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Design and Clinical Evaluation of a School Meal With Deworming Properties
Brief Summary: Intestinal parasites (IP) are among the world's neglected tropical diseases. Morbidity due to IPs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) of antihelminthic drugs to deworm children in developing countries. Though initially effective, there is concern that MDA might not be sustainable over extended periods especially considering the large children populations and the high frequency of dosing. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist anthelmintic drugs. There is hence a need for alternatives that are not only affordable and sustainable but easier to implement in the long term with a minimal chance of development of resistance. The investigators propose to develop and test the feasibility of a corn porridge meal fortified with papaya fruit extracts that have been shown to have antihelminthic properties. The investigators intend to evaluate its efficacy when given through school feeding programs and compare the outcome with albendazole- the recommended MDA agent for deworming school children. The investigators will design and formulate the product and test it among children in three primary schools in Western Kenya.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Drug: Praziquantel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current standard of care in Kenya | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Praziquantel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Current standard of care in Kenya; Assigned to Arm(s): 2
B: Arm Label: Papaya seed porridge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ujiplus | Arm Label: Albendazole and Plain porridge; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Arm Label: Plain porridge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: uji | Intervention Type: DIETARY_SUPPLEMENT; Name: Ujiplus; Assigned to Arm(s): Papaya seed porridge | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole and Plain porridge | Intervention Type: DIETARY_SUPPLEMENT; Name: uji; Assigned to Arm(s): Plain porridge
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Mebendazole; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): Mebendazole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
Brief Summary: The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) gene mutation.


Options:
A: Arm Label: Part A: 3 to <24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Arm Label: Part B + A/B:1 to < 24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: 3 to <24 months, Part B + A/B:1 to < 24 months
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration: a Randomized Controlled Trial
Brief Summary: This is a randomized controlled double-blind placebo-controlled trial evaluating the impact of gabapentin given preoperatively on perioperative pain scores for women receiving uterine aspiration between 6 and 14+6 weeks gestation. This study will be a trial included in a prospective meta-analysis evaluating the use of gabapentin on perioperative pain in the abortion setting.


Options:
A: Arm Label: Active Comparator; Type: EXPERIMENTAL; Interventions: Drug: vaginal 2% Xylocaine | Arm Label: standard lidocaine paracervical block; Type: OTHER; Interventions: Drug: standard lidocaine paracervical block | Intervention Type: DRUG; Name: vaginal 2% Xylocaine; Assigned to Arm(s): Active Comparator | Intervention Type: DRUG; Name: standard lidocaine paracervical block; Assigned to Arm(s): standard lidocaine paracervical block
B: Arm Label: No Paracervical Block for Pain Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Paracervical Block | Arm Label: Paracervical Block for Pain Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paracervical Block | Intervention Type: PROCEDURE; Name: Paracervical Block; Assigned to Arm(s): Paracervical Block for Pain Control | Intervention Type: PROCEDURE; Name: Sham Paracervical Block; Assigned to Arm(s): No Paracervical Block for Pain Control
C: Arm Label: Gabapentin group; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Group 1: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group 2: Gabapentin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Group 2: Gabapentin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tocolytic Therapy for Preterm Labor in Multiple Gestation
Brief Summary: To compare the tocolytic efficacy oxytocin receptor antagonist (Atosiban) with that of calcium channel blockers (Nifedipine) among women with multiple gestation who present with threatened preterm labor.


Options:
A: Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine 20 Mg | Arm Label: Ritodrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ritodrine Oral Tablet | Intervention Type: DRUG; Name: Nifedipine 20 Mg; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Ritodrine Oral Tablet; Assigned to Arm(s): Ritodrine
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral Nifedipine or placebo | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oral Nifedipine or placebo; Assigned to Arm(s): 2
C: Arm Label: Atosiban; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin

Answer: C